MHUAFOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies Co., Ltd. is a medical technology company with operating roots in China and a U.S.-incorporated subsidiary used to support its cross-border expansion. Its business includes the research, development, manufacturing, and sale of disposable medical devices, alongside a newer SaaS-oriented offering for medical registration and related digital services.

Liikevaihto61,8milj. USD
−36,2 %v/v
Liikevoitto (EBIT)8,3milj. USD
−42,1 %v/v
EBIT-marginaali13,4%
−1,4 %-yks.v/v
Nettotulos6,8milj. USD
−37,5 %v/v
Vapaa kassavirta0,6milj. USD
−96,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

0255075100125milj. USD2020: 89 milj. USD2020: EBIT 23 milj. USD20202021: 104 milj. USD2021: EBIT 26 milj. USD20212022: 103 milj. USD2022: EBIT 11 milj. USD20222023: 97 milj. USD2023: EBIT 15 milj. USD20232024: 97 milj. USD2024: EBIT 14 milj. USD20242025: 62 milj. USD2025: EBIT 8,3 milj. USD2025628,3
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Disposable Medical Devices97 %

Single-use medical devices manufactured and sold through the company’s China-based operations.

Medical Registration SaaS3 %

Software subscriptions and related digital tools for medical registration and workflow support.

Value-Added Services0 %

Custom upgrades, consulting, and commercial empowerment services sold around the SaaS platform.

Tuotteet

Raportoitu · osuus liikevaihdosta
44,0%44,0%9,4%FY2025100 %
  • Produced44,0 %
  • Self Manufactured Products44,0 %
  • Direct Sales of Disposable Medical Devices9,4 %
  • Saa S Development Service2,6 %

Lähde: 20-F FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

The company sells to healthcare providers, device merchants, and SaaS distributors that need medical registration, workflow, and digital management tools. Its legacy device business serves hospital and clinical end markets in China, while its newer software offering is aimed at buyers across North America, Hong Kong, and Southeast Asia. The customer base reflects a mix of physical product purchasers and recurring software buyers with compliance and operational needs.

Healthcare providers

Hospitals, clinics, and other providers that buy medical devices and SaaS tools for registration and operations

Device merchants

Merchants that use the platform for medical registration, product information, and workflow support

SaaS distributors

Channel partners that distribute the company’s medical SaaS systems

Mid- and small clinics

Smaller practices targeted for standardized cloud tools and compliance support

Strategia

The company is transitioning from a device-centric business toward a SaaS-led model that can generate subscription and value-added service revenue. Its strategy emphasizes medical registration software, remote consultation, AI tools, and commercial empowerment services to deepen customer relationships and broaden monetization. The U.S. subsidiary is intended to support cross-border commercialization and regulatory localization in target markets.

Expand medical registration SaaS salesLyhyt aikaväli

Recurring software revenue can diversify the business away from pure device sales

Grow value-added servicesKeskipitkä aikaväli

Custom services can increase revenue per customer and improve platform stickiness

Localize overseas commercializationKeskipitkä aikaväli

A U.S. operating base can improve compliance and customer adoption in target markets

Maantiede

The company’s established manufacturing and device sales operations are based in China, where its operating subsidiaries produce disposable medical devices. It is also building a U.S.-based SaaS business through Meihua Future, with planned sales across North America, Hong Kong, and Southeast Asia. Geography matters because the SaaS model depends on local compliance, customer trust, and digital infrastructure in each target market.

Riskit

The company faces execution risk as it moves into an early-stage SaaS business while maintaining its legacy medical device operations. Its results are exposed to regulatory change, technology performance issues, and adoption risk in new markets, while the device business remains sensitive to manufacturing quality, supply continuity, and healthcare demand cycles. Cross-border expansion also raises compliance, infrastructure, and cybersecurity risks.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Early-stage SaaS commercialization1Regulatory and compliance risk2Product and system performance risk3Operational and supply-chain disruption4Cybersecurity and infrastructure risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Early-stage SaaS commercializationVaikutus: KorkeaTodennäköisyys: Korkea

    The software business is new and still being tested commercially, so demand and retention are uncertain

    KohdistuuNorth AmericaHong KongSoutheast Asia
  2. Regulatory and compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Medical devices and medical software are both regulated and can face country-specific approval requirements

    Kohdistuu: China and overseas markets

  3. Product and system performance riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Delays in enhancements or weak system performance could damage customer trust and limit adoption

    Kohdistuu: SaaS platform

  4. Operational and supply-chain disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Device manufacturing depends on uninterrupted operations, quality control, and logistics

    Kohdistuu: Disposable medical devices

  5. Cybersecurity and infrastructure riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Software platforms require reliable infrastructure and protection from outages or attacks

    Kohdistuu: SaaS business

Kysy Clarifolta: Meihua International Medical Technologies Co., Ltd.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

Device sales and SaaS subscriptions likely follow different recognition patterns, affecting quarterly comparability

Vaikutus: Reported revenue timing and deferred revenue balances

Contract allocation

Bundled software, upgrades, and services may require judgment in assigning transaction prices

Vaikutus: Revenue mix and margin presentation

Software development capitalization

Costs tied to platform development may be capitalized or expensed depending on technical criteria

Vaikutus: Operating expenses and intangible assets

Impairment and provisions

An early-stage SaaS initiative may require judgments on recoverability and expected losses

Vaikutus: Asset values and earnings volatility

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 28.9.2026

Meihua International Medical Technologies Co., Ltd. (OTC) – Surgical & Medical Instruments & Apparat | Analyysi – Clarifo